FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Published:2013-08 Issue:8 Volume:24 Page:2062-2067
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fornaro L.,Lonardi S.,Masi G.,Loupakis F.,Bergamo F.,Salvatore L.,Cremolini C.,Schirripa M.,Vivaldi C.,Aprile G.,Zaniboni A.,Bracarda S.,Fontanini G.,Sensi E.,Lupi C.,Morvillo M.,Zagonel V.,Falcone A.

Funder

Gruppo Oncologico Nord Ovest

Azioni, Ricerche e Cure per l'Oncologia

Amgen

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/8/2062/13789942/mdt165.pdf

Reference21 articles.

1. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy;Kopetz;J Clin Oncol,2009

2. Emerging VEGF-receptor inhibitors for colorectal cancer;Martinelli;Expert Opin Emerg Drugs,2013

3. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer;De Roock;Lancet Oncol,2011

4. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

5. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis;Johnson;Lancet Oncol,2006

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study;Frontiers in Oncology;2024-04-04

2. The effective combination therapies with irinotecan for colorectal cancer;Frontiers in Pharmacology;2024-02-05

3. Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial;British Journal of Cancer;2023-11-23

4. Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis;World Journal of Surgical Oncology;2023-11-18

5. The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials;World Journal of Surgical Oncology;2023-10-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3